Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
24 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):51. 25 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):51. 26 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No.RR-6):10. 27 Brudkey K, Dobkin J. Resurgent tuberculosis in New York City. Am Rev Respir Dis 1991;144:745-749; In: Isake, L. Introduction to the symposium. Alcoholism and tuberculosis: an overview. Alcohol Clin Exp Res February 1995;19(1):1–2. 28 Saukkonen, JJ, Cohn, DL, Jasmer, RM, Schenker, S, Jereb, JA, Nolan, CM, Peloquin, CA, et al. An official ATS statement: hepatoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:937. 29 Saukkonen, JJ, Cohn, DL, Jasmer, RM, Schenker, S, Jereb, JA, Nolan, CM, Peloquin, CA, et al. An official ATS statement: hepatoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:947. 30 Saukkonen, JJ, Cohn, DL, Jasmer, RM, Schenker, S, Jereb, JA, Nolan, CM, Peloquin, CA, et al. An official ATS statement: hepatoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935. 31 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No.RR-6):16-18. 32 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):20-21. 33 Saukkonen, JJ, Cohn, DL, Jasmer, RM, Schenker, S, Jereb, JA, Nolan, CM, Peloquin, CA, et al. An official ATS statement: hepatoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:937. 34 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):24. 35 Saukkonen, JJ, Cohn, DL, Jasmer, RM, Schenker, S, Jereb, JA, Nolan, CM, Peloquin, CA, et al. An official ATS statement: hepatoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935. 36 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):10. 37 Brudkey K, Dobkin J. Resurgent tuberculosis in New York City. Am Rev Respir Dis 144:745-749, 1991. In: Isake, L. Introduction to the symposium. Alcoholism and tuberculosis: an overview. Alcohol Clin Exp Res February 1995;19(1):1–2. 38 Gelmanova, IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, Atwoodr S, Murray M. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bulletin of the World Health Organization September 2007;85(9):647–732. Accessed January 8, 2008. Available at: http://www.who.int/bulletin/volumes/85/9/06-038331/en/index.html. 39 Gelmanova, IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, Atwoodr S, Murray M. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bulletin of the World Health Organization September 2007;85(9):647–732. Accessed January 8, 2008. Available at: http://www.who.int/bulletin/volumes/85/9/06-038331/en/index.html. 40 CDC. Approaches to improving adherence to antituberculosis therapy – South Carolina and New York, 1986-1991. MMWR 1993;42(04):74–75, 81. 41 Saukkonen, JJ, Cohn, DL, Jasmer, RM, Schenker, S, Jereb, JA, Nolan, CM, Peloquin, CA, et al. An official ATS statement: hepatoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935. 42 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):65. 43 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):11. 44 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):63–64. 45 CDC. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002–2003. MMWR 2004;53(No. 30):683. 46 CDC. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002–2003. MMWR 2004;53(No. 30):685. 47 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):61. 48 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):61. 49 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):6, 61. 50 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):52. 51 Blumberg, HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005;293:2776-84.) 52 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):10. 53 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):57. 54 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):10, 57, 58–59. 55 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):10. 56 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):57. 57 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):62–63. 58 ATS, CDC, IDSA. Treatment of tuberculosis. MMWR 2003;52(No. RR-11):11. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Treatment of Tuber culosis Disease 6.41 Revised November 2012
Diagnosis of Latent Tuberculosis Infection CONTENTS Introduction ............................................. 7.2 Purpose................................................................ 7.2 Policy ................................................................... 7.2 Forms ................................................................... 7.3 Tuberculosis Classification System ..... 7.4 High-Risk Groups ................................... 7.5 Diagnosis of Latent Tuberculosis Infection ................................................... 7.7 Mantoux tuberculin skin testing ........................... 7.7 Candidates for Mantoux tuberculin skin testing .......................................................... 7.8 Administration of the tuberculin skin test ........... 7.11 Measurement of the tuberculin skin test .......... 7.12 Interpretation of the tuberculin skin test ............. 7.13 Human immunodeficiency virus screening ........ 7.15 Follow-up activities ............................................. 7.15 Interferon gamma release assays ...................... 7.16 Chest radiography .............................................. 7.17 Chest X-ray interpretation and treatment recommendations .............................................. 7.18 Work or school clearance .................................. 7.20 Resources and References ................. 7.21 A L A S K A T U B E R C U L O S I S C O N T R O L P R O G R A M M A N U A L Diagnosis of Latent Tuber culosis Infection R e v i s e d N o v e m b e r 2 0 1 2 7 . 1
- Page 81 and 82: 1. Exposure to Infectious TB: Ask p
- Page 83 and 84: Physical Examination A physical exa
- Page 85 and 86: For more information on chest radio
- Page 87 and 88: Laboratories should report positive
- Page 89 and 90: Guidelines for preventing the trans
- Page 91 and 92: 50 CDC. National plan for reliable
- Page 93 and 94: Introduction Purpose The overall go
- Page 95 and 96: Basic Treatment Principles Follow t
- Page 97 and 98: Treatment Regimens and Dosages Use
- Page 99 and 100: Table 3: FOUR TREATMENT REGIMENS FO
- Page 101 and 102: † 4 Table 4: DOSES*OF FIRST-LINE
- Page 103 and 104: Figure 1:TREATMENT ALGORITHM FOR DR
- Page 105 and 106: a. In remote locations in Alaska, m
- Page 107 and 108: Antituberculosis Drug Rifampin (RIF
- Page 109 and 110: Antituberculosis Drug Rifapentine (
- Page 111 and 112: Reporting Reactions The table below
- Page 113 and 114: Response to Treatment For consultat
- Page 115 and 116: Figure 2: MANAGEMENT OF TREATMENT I
- Page 117 and 118: Post-Treatment Evaluation Routine f
- Page 119 and 120: Treatment in Special Situations Tre
- Page 121 and 122: Resources For consultation regardin
- Page 123 and 124: with an increase in overall complet
- Page 125 and 126: Liver Disease Management of TB in p
- Page 127 and 128: After the initial phase (first two
- Page 129 and 130: Extrapulmonary Tuberculosis The bas
- Page 131: Resources and References Resources
- Page 135 and 136: Forms All required and recommended
- Page 137 and 138: High-Risk Groups Certain factors id
- Page 139 and 140: Diagnosis of Latent Tuberculosis In
- Page 141 and 142: continually exposed to populations
- Page 143 and 144: Administration of the Tuberculin Sk
- Page 145 and 146: See “Two-Step Tuberculin Skin Tes
- Page 147 and 148: See “Live-Virus Vaccines” under
- Page 149 and 150: For more information on IGRAs and t
- Page 151 and 152: Table 5: TARGETED TESTING FOR LATEN
- Page 153 and 154: Resources and References Resources
- Page 155 and 156: Treatment of Latent Tuberculosis In
- Page 157 and 158: Policy Detailed information on the
- Page 159 and 160: Window period prophylaxis is treatm
- Page 161 and 162: Regimens Identify an appropriate re
- Page 163 and 164: Dosages Once the appropriate regime
- Page 165 and 166: Side Effects and Adverse Reactions
- Page 167 and 168: If a patient reports to a healthcar
- Page 169 and 170: Antituberculosis Drug Rifampin (RIF
- Page 171 and 172: DOT is strongly encouraged for thos
- Page 173 and 174: Table 7 describes the duration of t
- Page 175 and 176: Alcoholism Alcohol-Related Treatmen
- Page 177 and 178: Medication Administration and Pharm
- Page 179 and 180: National Tuberculosis Controllers A
- Page 181 and 182: 24 CDC . “Recommendations for Use
Diagnosis <strong>of</strong><br />
Latent <strong>Tuberculosis</strong> Infection<br />
CONTENTS<br />
Introduction ............................................. 7.2<br />
Purpose................................................................ 7.2<br />
Policy ................................................................... 7.2<br />
Forms ................................................................... 7.3<br />
<strong>Tuberculosis</strong> Classification System ..... 7.4<br />
High-Risk Groups ................................... 7.5<br />
Diagnosis <strong>of</strong> Latent <strong>Tuberculosis</strong><br />
Infection ................................................... 7.7<br />
Mantoux tuberculin skin testing ........................... 7.7<br />
Candidates for Mantoux tuberculin<br />
skin testing .......................................................... 7.8<br />
Administration <strong>of</strong> the tuberculin skin test ........... 7.11<br />
Measurement <strong>of</strong> the tuberculin skin test .......... 7.12<br />
Interpretation <strong>of</strong> the tuberculin skin test ............. 7.13<br />
Human immunodeficiency virus screening ........ 7.15<br />
Follow-up activities ............................................. 7.15<br />
Interferon gamma release assays ...................... 7.16<br />
Chest radiography .............................................. 7.17<br />
Chest X-ray interpretation and treatment<br />
recommendations .............................................. 7.18<br />
Work or school clearance .................................. 7.20<br />
Resources and References ................. 7.21<br />
A L A S K A T U B E R C U L O S I S C O N T R O L P R O G R A M M A N U A L Diagnosis <strong>of</strong> Latent Tuber culosis Infection<br />
R e v i s e d N o v e m b e r 2 0 1 2<br />
7 . 1
Change language